Newer antiepileptic drugs and cognitive issues

Epilepsia

Volumn 44, Issue SUPPL. 4, 2003, Pages 21-29

  Aldenkamp, Albert P ^a,b,c,d   De Krom, Marc ^b   Reijs, Rianne ^b  

^a EPILEPSY CENTER KEMPENHAEGHE   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptic drugs; Cognitive function; Lamotrigine; Oxcarbazepine; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADD ON THERAPY; AGE; ATTENTION; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE CONTROL; DOSE RESPONSE; DRIVING ABILITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG SALIVA LEVEL; DRUG TOLERABILITY; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAM; EPILEPSY; EPILEPTIC DISCHARGE; EYE HAND COORDINATION; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GRAND MAL EPILEPSY; HUMAN; INTELLIGENCE TEST; LEARNING; LONG TERM MEMORY; MEMORY; MEMORY DISORDER; MENTAL CAPACITY; MENTAL DEFICIENCY; META ANALYSIS; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SOMNOLENCE; SPEECH DISORDER; TREATMENT OUTCOME; VERBAL BEHAVIOR; WRITING;

EID: 0038153927     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.44.s4.3.x     Document Type: Conference Paper

References (65)

1. Aldenkamp AP, Dodson WE, eds. Epilepsy and education; cognitive factors in learning behavior. Epilepsia 1990;31 (suppl 4):S9-20.
2. Dodson WE, Pellock JM. Pediatric epilepsy: diagnosis and treatment. New York: Demos Publications, 1993.
3. Rapin I. Children with brain dysfunction: neurology, cognition, language and behavior. New York: Raven Press, 1982.
4. Dodson WE, Trimble MR. Epilepsy and quality of life. New York: Raven Press, 1994.
5. Aldenkamp AP, Dreifuss FE, Renier WO, Suumeijer PBM. Epilepsy in children and adolescents. Boca Raton, FL: CRC Press, 1995.
6. Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures-effects on cognitive function. In: Trimble M, Schmitz B, eds. The neuropsychiatry of epilepsy. New York: Cambridge University Press, 2002:256-67.
7. Ideström CM, Schalling D, Carlquist U, Sjoqvist F. Acute effects of diphenylhydantoin in relation to plasma levels. Behavioral and psychological studies. Psychol Med 1972;2:111-20.
8. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27:1023-8.
9. Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995;22:65-95.
10. Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987;28(suppl 3):37-45.
11. Aldenkamp AP, Alpherts WCJ, Blennow G, et al. Withdrawal of antiepileptic medication - effects on cognitive function in children: The Multicentre Holmfrid Study. Neurology 1993;43:41-50.
12. Meador KJM, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-4.
13. American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on Drugs. Pediatrics 1985;76:644-7.
14. Loescher W, Schmidt D. New horizons in the development of antiepileptic drugs. Epilepsy Res 2002;50:3-16.
15. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-83.
16. Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(3):CD001417.
17. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.
18. Wong IC. New antiepileptic drugs. Study suggests that under a quarter of patients will still be taking the new drugs after six years. Br M J 1997;314:603-4.
19. Lhatoo SD, Wong ICK, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41:338-41.
20. Stefan H, Krämer G. Mamoli B, eds. Challenge epilepsy - new antiepileptic drugs. Berlin: Blackwell Science, 1998.
21. Kellet MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:759-63.
22. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000;(2):CD001415.
23. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001;46:259-70.
24. Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37(suppl 6):S17-22.
25. Aldenkamp AP. Cognitive and behavioural assessment in clinical trials: when should they be done? Epilepsy Res 2000;45:155-9.
26. Gallassi R, Morreale A, Di Sarro R, Marra M, Lugaresi E, Baruzzi A. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992;33(suppl 6):S41-4.
27. Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Eur J Clin Pharmacol 1993;44:529-33.
28. Laaksonen R, Kaimola K, Grahn-Teräväinen E, Waltimo O. A controlled clinical trial of the effects of carbamazepine and oxcarbazepine on memory and attention [Abstract]. 16th International Epilepsy Congress, Hamburg, 1985.
29. Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995;92:19-27.
30. Äikiä M, Kälviäinen R, Sivenius J, Halonen T, Riekkinen RJ. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992;11:199-203.
31. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994;37:27-32.
32. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S9-17.
33. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
34. Aldenkamp AP. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 2000;54:270-2.
35. Aldenkamp AP, Baker G, Mulder OG, et al. A multicentre randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167-78.
36. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53(5 suppl 2):53-67.
37. Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
38. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 1999;52:321-7.
39. Meador KJ. Assessing cognitive effects of a new AED without the bias of practice effects [Abstract]. Epilepsia 1997;38(suppl 3):60.
40. Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997;27:29-32.
41. Thompson PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000;69:636-41.
42. Aldenkamp AP, Baker G. A systematic review of the effects of lamotrigine on cognitive function and quality of life. Epilepsy Behav 2001;2:85-91.
43. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985;20:619-29.
44. Hamilton MJ, Cohen AF, Yuen AW, et al. Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 1993;34:166-73.
45. Meador KJ, Loring DW, Ray PG, Perrine KR, Bazquez BR, Kalbosa T. Differential effects of carbamazepine and lamotrigine [Abstract]. Neurology 2000;54(suppl 3):A84.
46. Aldenkamp AP, Arends J, Bootsma HP, et al. Randomized, double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002;43:19-26.
47. Gillham R, Kane K, Bryant-Comstock L, Brodie MJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000;9:375-9.
48. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
49. Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991;28:230-7.
50. Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of lamotrigine as first line add-on in patients with localized related (partial) epilepsy. J Epilepsy 1997;10:117-21.
51. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-7.
52. Earl N, McKee JR, Sunder TR, et al. Lamotrigine adjunctive therapy in patients with refractory epilepsy and mental retardation [Abstract]. Epilepsia 2000;41(suppl 1):72.
53. Aarts JH, Binnie CD, Smit AM, Wilkins AJ. Selective cognitive impairment during focal and generalized epileptiform EEG activity. Brain 1984;107:293-308.
54. Aldenkamp AP, Arends J, Overweg-Plandsoen TC, et al. Acute cognitive effects of nonconvulsive difficult-to-detect epileptic seizures and epileptiform electroencephalographic discharges. J Child Neurol 2001;16:119-23.
55. Binnie CD, Emde BW, Kasteleijn-Nolste-Trenite DG, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
56. Marciani MG, Spanedda F, Bassetti MA, et al. Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Br J Clin Pharmacol 1996;42:621-7.
57. Marciani MG, Stanzione P, Mattia D, et al. Lamotrigine add-on therapy in focal epilepsy: electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21:41-7.
58. Mervaala E, Koivista K, Hanninen T, et al. Electrophysiological and neuropsychological profiles of lamotrigine in young and age-associated memory impairment (AAMI) subjects [Abstract]. Neurology 1995;45(suppl 4):A259.
59. Neyens LGJ, Alpherts WCJ, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:411-9.
60. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
61. Kälviäinen R, Äikiä M, Mervaala E, Saukkonen AM, Pitkanen A, Riekkinen PJ Sr. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996;25:291-7.
62. Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:29-35.
63. Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40:1279-85.
64. Leach JP, Girvan J, Paul A, Brodie MJ. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997;62:372-6.
65. Mortimore C, Trimble M, Emmers E. Effects of gabapentin on cognition and quality oflife in patients with epilepsy. Seizure 1998;7:35964.